ARGNF Stock Price, Chart, Stats & News

argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's flagship investigational therapy is efgartigimod, currently undergoing Phase III clinical trials for conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Efgartigimod is also in Phase II/III studies for bullous pemphigoid and idiopathic inflammatory myopathy, with a subcutaneous formulation (ENHANZE SC) in preclinical development.